Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW")...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced Dr. Stefanie Johns, who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled to...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing the intellectual property rights relating to the development of a medical device that has the...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development,...
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor...
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at...
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö"). Mr. Robb Knie, Chief Executive...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m....